Brazil is no longer just on the periphery of the global biotech conversation. The country has emerged as Latin America's most active cell and gene therapy (CGT) hub, backed by regulatory momentum, a large patient population, and rising institutional investment. For businesses and investors tracking high-growth healthcare markets, this one deserves a serious look.Request Sample For PDF Report: www.imarcgroup.com/brazil-cell-gene-therapy-market/requestsample
According to IMARC Group, The Brazil cell and gene therapy market size reached USD 298.30 Million in 2025. The market is projected to reach USD 794.01 Million by 2034, exhibiting a growth rate (CAGR) of 11.49% during 2026-2034.
Why the Brazil Cell and Gene Therapy Market Is Growing
Brazil was the first country in Latin America to approve gene therapy products commercially. ANVISA, the Brazilian Health Regulatory Agency, granted marketing authorization for Novartis' Luxturna and Zolgensma, both of which passed review by the Brazilian Technical Commission of Biosafety (CTNBio). That regulatory first-mover position has continued to attract multinational CDMOs and clinical research organisations to set up local operations.
Visit us: www.imarcgroup.com/brazil-cell-gene-therapy-market
Brazil Cell and Gene Therapy Market Segmentation:
Therapy Type Insights:
Cell Therapy
Stem Cell
Pluripotent Stem Cell
Cancer Stem Cell
Adult Stem Cell
Non-stem Cell
T-cell
Natural Killer Cell
Others
Gene Therapy
Indication Insights:
Cardiovascular Disease
Oncology Disorder
Genetic Disorder
Infectious Disease
Neurological Disorder
Others
Delivery Mode Insights:
In-vivo
Ex-vivo
End User Insights:
Hospitals
Cancer Care Centers
Pharmaceuticals and Biotechnology Companies
Others
Regional Insights:
Southeast
South
Northeast
North
Central-West
Latest Industry News and Developments
1. Caring Cross and Fiocruz Partnership for Local CAR-T Manufacturing
In March 2024, U.S.-based nonprofit Caring Cross entered into an agreement with Fiocruz to build out domestic manufacturing capacity for CAR-T cell and stem cell gene therapies within Brazil. This marks a significant step toward reducing dependency on expensive imports and making these treatments more accessible to Brazilian patients.
2. Boston CRO Expands into Brazil via IBPClin Acquisition
Boston CRO acquired Rio de Janeiro-based Instituto Brasil de Pesquisa Clinica (IBPClin), which has conducted over 160 industry-sponsored studies across 12 Brazilian states, enrolling more than 7,000 participants. This acquisition signals a broader push toward decentralised clinical trial delivery across Latin America, with Brazil as the anchor.